Your device screen is too small.
The ROADMAP tool can be viewed on devices such as larger tablets, laptops, and computers. (If you're currently on a computer/laptop, make sure the page is full screen.) We apologize for any inconvenience.
Identification
Identification: Drug screen
Identification: Pathogenesis targeting
Identification: Data from similar diseases
Identification: Computational
Identification: Off-label use
Validation
Validation: In vivo
Validation: In vitro
Validation: Evaluation of RWE
Clinical Use
Clinical Use: Clinical trial
Clinical Use: Off-label use
Outcomes
Outcomes: Approvals
Outcomes: Alteranatives
Outcomes: Abandoned
Drug Repurposing ROADMAP
A subtitle of some sort
There are ∼7000 rare diseases affecting approximately 30,000,000 individuals in the U.S.A. and 95% of these rare diseases do not have a single Food and Drug Administration-approved therapy. Since the incentives for new drug development for rare diseases are limited, drug repurposing provides a promising way to identify effective treatments for rare diseases faster and cheaper than developing new drugs. Still, many challenges exist in the drug repurposing space.
The Repurposing Of All Drugs, Mapping All Paths (ROADMAP) project proposes to fill some of these knowledge gaps through document analysis, surveys and interviews grounded in a participatory design approach. Ultimately, this project aims to not only answer some fundamental questions about the experience of drug repurposing for various stakeholders, but to also design a solution to some of the challenges rare disease organizations are facing through the creation of an interactive tool.